Celgene Stock

CELG

Delayed Nasdaq 08:00:00 21/11/19 am AEDT			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

15/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

07/04/21	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
25/03/21	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
02/02/21	BX Swiss AG startet Handel in neuem Bondsegment
07/07/20	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
03/07/20	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 66.1B 62.02B 56.66B 107B 7,349B 107B 733B 285B 3,707B 289B 283B 12,270B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 78.31B 73.47B 67.12B 127B 8,706B 127B 869B 337B 4,391B 343B 335B 14,536B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

15/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
22/06/21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
23/02/21	Celgene Corporation Issues Notice of Redemption of Notes	CI
04/02/21	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
05/01/21	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
23/12/20	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
06/11/20	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
23/09/20	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
22/09/20	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
26/03/20	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
11/03/20	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
05/03/20	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

28/02/23	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
25/08/22	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/07/22	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
25/02/22	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
05/08/21	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.16B 10.47B 9.56B 18.04B 1,241B 18.12B 124B 48.06B 626B 48.82B 47.76B 2,071B	15.28B 13.11B 12.3B 11.24B 21.2B 1,458B 21.29B 145B 56.48B 735B 57.37B 56.12B 2,434B
Net income	2.94B 2.52B 2.37B 2.16B 4.08B 280B 4.1B 27.98B 10.87B 141B 11.04B 10.8B 468B	4.05B 3.47B 3.26B 2.98B 5.61B 386B 5.64B 38.51B 14.96B 195B 15.19B 14.86B 644B
Net Debt	3.79B 3.25B 3.05B 2.79B 5.26B 362B 5.28B 36.1B 14.02B 183B 14.24B 13.93B 604B	14.22B 12.2B 11.45B 10.46B 19.73B 1,357B 19.81B 135B 52.57B 684B 53.39B 52.23B 2,265B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile